SCHEMBL7120883

SCHEMBL7120883

Cc1ncc(-c2cccc(Nc3ncc(Cc4cccs4)c4ccccc34)c2)n1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK2 O43353 3/20 0.42
FYN P06241 6/20 0.37
CYP1A2 P05177 3/20 0.34
CYP3A4 P08684 3/20 0.34
CYP2D6 P10635 3/20 0.34
CYP2C9 P11712 3/20 0.34
CYP2C19 P33261 3/20 0.34
HSD17B10 Q99714 2/20 0.34
KDM4E B2RXH2 2/20 0.34
USP2 O75604 2/20 0.34
LMNA P02545 2/20 0.34
MAPK1 P28482 2/20 0.34
EGFR P00533 1/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34
ALOX15 P16050 1/20 0.34
TSHR P16473 1/20 0.34
TDP1 Q9NUW8 1/20 0.33
NPC1 O15118 2/20 0.33
ALDH1A1 P00352 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7120296 0.85 RIPK2 (0.41) RIPK2CYP1A2EGFRMAPTNPC1
SCHEMBL7129801 0.74 RIPK2 (0.48) RIPK2FYNKDM4ELMNAEGFR
SCHEMBL7127543 0.73 KDR (0.54) EGFRNPC1ALDH1A1RAB9AMEN1
SCHEMBL7127650 0.73 MAPT (0.46) RIPK2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL7124246 0.72 RIPK2 (0.43) RIPK2KDM4ELMNAMAPK1EGFR
SCHEMBL7119935 0.72 RIPK2 (0.41) RIPK2FYNTTK
SCHEMBL7128079 0.70 KDR (0.52) MEN1KMT2A
SCHEMBL7160086 0.70 RIPK2 (0.41) RIPK2FYNKDM4ELMNAEGFR
SCHEMBL7125034 0.69 RIPK2 (0.42) RIPK2FYNCYP1A2CYP3A4CYP2D6
SCHEMBL7127458 0.69 ALDH1A1 (0.42) RIPK2CYP1A2CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030176454-A1 N-coating heterocyclic compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-09-18 US disclosed
WO-2001087845-A2 N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176454-A1 N-coating heterocyclic compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 RIPK2 3457/4885FYN 817/4885CYP1A2 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.